Tennessee Oncology

InstitutionResearch output, impact & collaborations

Tennessee Oncology is a research organisation in Nashville, US. OpenAlex records 3,841 works and 371,118 citations for it. 539 researchers list it as their most recent affiliation.

3,841

Works

371,118

Citations

539

Researchers

91.5

Avg h-index

IDs:ROR OpenAlex

How has Tennessee Oncology's publication output changed over time?

ScholarIQpublication output · 2015–2021

Output declined33% over the shown period — from 3 works in 2015 to 2 in 2021.

2015201620182021

What are the most-cited papers on Tennessee Oncology?

ScholarIQmost cited works

Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation

Navneet S. Majhail, Stephanie Farnia, Paul A. Carpenter, Richard E. Champlin, Stephen W. Crawford, David I. Marks, James Omel, Paul J. Orchard, Jeanne Palmer, Wael Saber, Bipin N. Savani, Paul Veys, Christopher Bredeson, Sergio Giralt, C. Frederick LeMaistre

S59987174. 2015411 CitationsOPEN ACCESS

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Franck Morschhauser, Nathan Fowler, Pierre Feugier, Réda Bouabdallah, Hervé Tilly, M. Lia Palomba, Christophe Fruchart, Edward N. Libby, Olivier Casasnovas, Ian W. Flinn, Corinne Haïoun, Hervé Maisonneuve, Loïc Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Nicolas Daguindau, Steven Le Gouill, Gian M. Pica, Alejandro Martı́n, Armando López‐Guillermo, Jean-François Larouche, Kiyoshi Ando, María Gomes da Silva, Marc André, Pierre Zachée, Laurie H. Sehn, Kensei Tobinai, Guillaume Cartron, David Liu, Jianming Wang, Luc Xerri, Gilles Salles

New England Journal of Medicine. 2018366 CitationsOPEN ACCESS

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles, Sarit Assouline, Laurie H. Sehn, Ian W. Flinn, Manish R. Patel, Randeep Sangha, Anton Hagenbeek, Ranjana H. Advani, Hervé Tilly, Olivier Casasnovas, Oliver W. Press, Sreeni Yalamanchili, Robert S. Kahn, Randall Dere, Dan Lü, Surai Jones, Cheryl Jones, Yu-Waye Chu, Franck Morschhauser

The Lancet Oncology. 2015335 Citations

Secondary solid cancer screening following hematopoietic cell transplantation

Yoshihiro Inamoto, Nirali N. Shah, Bipin N. Savani, Bronwen E. Shaw, Allistair Abraham, Ibrahim Ahmed, Görgün Akpek, Yoshiko Atsuta, K. Scott Baker, Grzegorz Basak, Menachem Bitan, Zachariah DeFilipp, Tara Gregory, Hildegard Greinix, Mehdi Hamadani, Betty K. Hamilton, Robert J. Hayashi, David A. Jacobsohn, Rammurti T. Kamble, Kimberly A. Kasow, Nandita Khera, Hillard M. Lazarus, Adriana K. Malone, Maria Teresa Lupo Stanghellini, Steven Margossian, Lori Muffly, Maxim Norkin, Muthalagu Ramanathan, Nina Salooja, Hélène Schoemans, John R. Wingard, Baldeep Wirk, William A. Wood, Agnes S. M. Yong, C. Duncan, Mary E.D. Flowers, Navneet S. Majhail

S183182149. 2015186 Citations

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

David P. Steensma, Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font, Rami S. Komrokji, Jay Yang, Andrew M. Brunner, Hetty E. Carraway, Lionel Adès, Aref Al‐Kali, Juan Manuel Alonso‐Domínguez, Ana Alfonso Piérola, Catherine C. Coombs, H. Joachim Deeg, Ian W. Flinn, James M. Foran, Guillermo Garcia‐Manero, Michael B. Maris, Malgorzata McMasters, Jean‐Baptiste Micol, Jaime Pérez de Oteyza, Felicitas Thol, Eunice S. Wang, Justin M. Watts, Justin Taylor, Richard M. Stone, Vikram Gourineni, Alyssa J. Marino, Huilan Yao, Benoit Destenaves, Xiaobin Yuan, Kun Yu, Sara Dar, Lernik Ohanjanian, Keisuke Kuida, Jianjun Xiao, Catherine Scholz, Antonio Gualberto, Uwe Platzbecker

S149476849. 2021184 CitationsOPEN ACCESS